Eltrombopag (Promacta), a thrombopoetin receptor agonist for the treatment of thrombocytopenia: Current and future considerations

American Journal of Therapeutics

Volumn 17, Issue 1, 2010, Pages 68-74

  Serebruany, Victor L ^a   Eisert, Christian ^a   Sabaeva, Elena ^a   Makarov, Leonid ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adverse events; Drug profile; Eltrombopag; Thrombocytopenia

Indexed keywords

ANTIBODY; BUTYRIC ACID DERIVATIVE; BUTYZAMIDE; DEXAMETHASONE; ELTROMBOPAG; GMA 161; INTERFERON; PLACEBO; PREDNISONE; PROTEIN KINASE SYK INHIBITOR; R 788; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ASCITES; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEPATITIS C; HUMAN; INFLUENZA; MAXIMUM PLASMA CONCENTRATION; MEGAKARYOCYTE; MORBIDITY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RETINAL EXUDATE; REVIEW; STROKE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; ARTICLE; BIOAVAILABILITY; DRUG EFFECT; DRUG POTENTIATION; HOSPITALIZATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; BENZOIC ACIDS; BIOLOGICAL AVAILABILITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; HUMANS; HYDRAZINES; MEGAKARYOCYTES; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA;

EID: 76149143471     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318199d6b7     Document Type: Review

References (17)

1. McCrae KR, ed. Thrombocytopenia. Philadelphia: Taylor & Francis; 2006.
2. Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14: 515-519.
3. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4:2377-2383.
4. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med. 1997;126:319-326.
5. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006;28:185-206.
6. Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol. 2007;44(Suppl 5):S35-45.
7. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739-4741.
8. McHutchison JG, Dusheiko G, Shiffman ML, et al. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227-2236.
9. Basser R. The impact of thrombopoietin on clinical practice. Curr Pharm Des. 2002;8:369-377.
10. Hashimoto S, Toba K, Fuse I, et al. Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome. Eur J Haematol. 2000;64:225-230.
11. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-2247.
12. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672-1681.
13. Nogami W, Yoshida H, Koizumi K, et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica. 2008;93:1495-1504.
14. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
15. Cheng Y,Wong R, Soo Y, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831-836.
16. Arnold D, Dentali F, Crowther M, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombcytopenic purpura. Ann Intern Med. 2007;146:25-33.
17. Peeters K, Stassen JM, Collen D, et al. Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discovery Today. 2008;13:798-806.